Biologicals in IgE-mediated food allergy.
Journal
Current opinion in allergy and clinical immunology
ISSN: 1473-6322
Titre abrégé: Curr Opin Allergy Clin Immunol
Pays: United States
ID NLM: 100936359
Informations de publication
Date de publication:
01 06 2023
01 06 2023
Historique:
medline:
17
5
2023
pubmed:
15
5
2023
entrez:
15
5
2023
Statut:
ppublish
Résumé
A better understanding of the most recent scientific literature in the use of biological therapy in the treatment of patients with IgE-mediated food allergy. A systematic review and meta-analysis demonstrated safety and effectiveness of omalizumab in the treatment of food allergy. The findings support the potential use of omalizumab as a monotherapy or as an adjunct to oral immunotherapy in IgE-mediated cow's milk allergy. The potential use of other biologics in the management of food allergy is subject of speculation. Different biological therapies are under evaluation for food allergic patients. The advance in literature will guide for a personalized treatment in the near future. However, additional research is needed to better understand the best candidate for each treatment, the optimal dose and timing.
Identifiants
pubmed: 37185824
doi: 10.1097/ACI.0000000000000900
pii: 00130832-202306000-00003
doi:
Substances chimiques
Omalizumab
2P471X1Z11
Biological Products
0
Immunoglobulin E
37341-29-0
Types de publication
Systematic Review
Meta-Analysis
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
205-209Informations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Références
Arasi S, Nurmatov U, Turner PJ, et al. Consensus on DEfinition of Food Allergy SEverity (DEFASE): protocol for a systematic review. World Allergy Organ J 2020; 13:100493.
Anvari S, Miller J, Yeh CY, Davis CM. IgE-mediated food allergy. Clin Rev Allergy Immunol 2019; 57:244–260.
Ansotegui IJ, Melioli G, Canonica GW, et al. IgE allergy diagnostics and other relevant tests in allergy, a World Allergy Organization position paper. World Allergy Organ J 2020; 13:100080.
Gupta RS, Warren CM, Smith BM, et al. Prevalence and severity of food allergies among US adults. JAMA Netw Open 2019; 2:e185630.
Pouessel G, Alonzo S, Divaret-Chauveau A, et al. Allergy-Vigilance® Network. Fatal and near-fatal anaphylaxis: the Allergy-Vigilance® Network data (2002–2020). Allergy 2023; [Epub ahead of print].
Muraro A, Werfel T, Hoffmann-Sommergruber K, et al. EAACI Food Allergy and Anaphylaxis Guidelines Group. EAACI food allergy and anaphylaxis guidelines: diagnosis and management of food allergy. Allergy 2014; 69:1008–1025.
Fiocchi A, Bognanni A, Brożek J, et al. WAO DRACMA guideline group. World Allergy Organization (WAO) Diagnosis and Rationale for Action against Cow's Milk Allergy (DRACMA) Guidelines update - I - Plan and definitions. World Allergy Organ J 2022; 15:100609.
Brozek JL, Firmino RT, Bognanni A, et al. World Allergy Organization (WAO) Diagnosis and Rationale for Action against Cow's Milk Allergy (DRACMA) Guideline update - XIV - Recommendations on CMA immunotherapy. World Allergy Organ J 2022; 15:100646.
Stiefel G, Anagnostou K, Boyle RJ, et al. BSACI guideline for the diagnosis and management of peanut and tree nut allergy. Clin Exp Allergy 2017; 47:719–739.
Leech SC, Ewan PW, Skypala IJ, et al. BSACI 2021 guideline for the management of egg allergy. Clin Exp Allergy 2021; 51:1262–1278.
Muraro A, de Silva D, Halken S, et al. GA2LEN Food Allergy Guideline Group; GALEN Food Allergy Guideline Group. Managing food allergy: GA2LEN guideline. World Allergy Organ J 2022; 15:100687.
Muraro A, Worm M, Alviani C, et al. European Academy of Allergy and Clinical Immunology, Food Allergy, Anaphylaxis Guidelines Group. EAACI guidelines: anaphylaxis (2021 update). Allergy 2022; 77:357–377.
Patel N, Herbert L, Green TD. The emotional, social, and financial burden of food allergies on children and their families. Allergy Asthma Proc 2017; 38:88–91.
Wai HM, Middelveld R, Thornqvist V, et al. Pediatric food allergy-related household costs are influenced by age, but not disease severity. World Allergy Organ J 2019; 12:100061.
Golding MA, Batac ALR, Gunnarsson NV, et al. The burden of food allergy on children and teens: a systematic review. Pediatr Allergy Immunol 2022; 33:e13743.
Polloni L, Muraro A. Anxiety and food allergy: a review of the last two decades. Clin Exp Allergy 2020; 50:420–441.
Fiocchi A, Vickery BP, Wood RA. The use of biologics in food allergy. Clin Exp Allergy 2021; 51:1006–1018.
Arasi S, Mennini M, Valluzzi R, et al. Precision medicine in food allergy. Curr Opin Allergy Clin Immunol 2018; 18:438–443.
Hu J, Chen J, Ye L, et al. Anti-IgE therapy for IgE-mediated allergic diseases: from neutralizing IgE antibodies to eliminating IgE(+) B cells. Clin Transl Allergy 2018; 8:27.
Lopes JP, Sicherer S. Food allergy: epidemiology, pathogenesis, diagnosis, prevention, and treatment. Curr Opin Immunol 2020; 66:57–64.
Tordesillas L, Berin MC, Sampson HA. Immunology of food allergy. Immunity 2017; 47:32–50.
Long A, Borro M, Sampath V, Chinthrajah RS. New developments in nonallergen-specific therapy for the treatment of food allergy. Curr Allergy Asthma Rep 2020; 20:3.
Kabata H, Motomura Y, Kiniwa T, et al. ILCs and allergy. Adv Exp Med Biol 2022; 1365:75–95.
Gon Y, Maruoka S, Mizumura K. Omalizumab and IgE in the control of severe allergic asthma. Front Pharmacol 2022; 13:839011.
Zuberbier T, Abdul Latiff AH, Abuzakouk M, et al. The international EAACI/GA 2 LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. Allergy 2022; 77:734–766.
Davies AM, Allan EG, Keeble AH, et al. Allosteric mechanism of action of the therapeutic anti-IgE antibody omalizumab. J Biol Chem 2017; 292:9975–9987.
Dantzer JA, Kim EH, Chinthrajah RS, Wood RA. Treatment for food allergy: current status and unmet needs. J Allergy Clin Immunol 2023; 151:1–14.
Pesek RD, Gupta SK. Future therapies for eosinophilic gastrointestinal disorders. Ann Allergy Asthma Immunol 2020; 124:219–226.
González-Pérez R, Poza-Guedes P, Mederos-Luis E, Sánchez-Machín I. Dupilumab modulates specific IgE mite responses at the molecular level in severe T2-high atopic dermatitis: a real-world experience. Front Med (Lausanne) 2022; 9:939598.
Spekhorst LS, van der Rijst LP, de Graaf M, et al. Dupilumab has a profound effect on specific-IgE levels of several food allergens in atopic dermatitis patients. Allergy 2022; [Epub ahead of print].
Zhou B, Dong J, Liang S, et al. The changes of IgE levels in type 2 inflammatory diseases after treatment of dupilumab: a systematic review and meta-analysis. Expert Rev Clin Pharmacol 2022; 15:1233–1242.
https://clinicaltrials.gov/ct2/show/NCT03682770 . [Accessed 2 January 2023]
https://clinicaltrials.gov/ct2/show/NCT03793608 . [Accessed 2 January 2023]
Berin C. Jak out of the box -targeting BTK, Siglec-8, & Jak1 in food allergy. Ann Allergy Asthma Immunol 2023; [Epub ahead of print].
Chinthrajah S, Cao S, Liu C, et al. Phase 2a randomized, placebo-controlled study of anti-IL-33 in peanut allergy. JCI Insight 2019; 4:e131347.
De Silva D, Singh C, Arasi S, et al. Systematic review of monotherapy with biologicals for children and adults with IgE-mediated food allergy. Clin Transl Allergy 2022; 12:e12123.
Corren J, Parnes JR, Wang L, et al. Tezepelumab in adults with uncontrolled asthma. N Engl J Med 2017; 377:936–946.
Uppal SK, Kearns DG, Chat VS, et al. Review and analysis of biologic therapies currently in phase II and phase III clinical trials for atopic dermatitis. J Dermatolog Treat 2022; 33:626–636.
Leung DY, Sampson HA, Yunginger JW, et al. Avon Longitudinal Study of Parents and Children Study Team. Effect of anti-IgE therapy in patients with peanut allergy. N Engl J Med 2003; 348:986–993.
Sampson HA, Leung DY, Burks AW, et al. A phase II, randomized, double-blind, parallel-group, placebo-controlled oral food challenge trial of Xolair (omalizumab) in peanut allergy. J Allergy Clin Immunol 2011; 127:1309–1310.
Fiocchi A, Artesani MC, Riccardi C, et al. Impact of Omalizumab on food allergy in patients treated for asthma: a real-life study. J Allergy Clin Immunol Pract 2019; 7:1901–1909.
https://clinicaltrials.gov/ct2/show/NCT03881696 . [Accessed 3 February 2023]
Dantzer JA, Wood RA. Omalizumab as an adjuvant in food allergen immunotherapy. Curr Opin Allergy Clin Immunol 2021; 21:278–285.
Nadeau KC, Schneider LC, Hoyte L, et al. Rapid oral desensitization in combination with omalizumab therapy in patients with cow's milk allergy. J Allergy Clin Immunol 2011; 127:1622–1624.
Bedoret D, Singh AK, Shaw V, et al. Changes in antigen-specific T-cell number and function during oral desensitization in cow's milk allergy enabled with omalizumab. Mucosal Immunol 2012; 5:267–276.
Wood RA, Kim JS, Lindblad R, et al. A randomized, double-blind, placebo-controlled study of omalizumab combined with oral immunotherapy for the treatment of cow's milk allergy. J Allergy Clin Immunol 2016; 137:1103–1110.
Takahashi M, Soejima K, Taniuchi S, et al. Oral immunotherapy combined with omalizumab for high-risk cow's milk allergy: a randomized controlled trial. Sci Rep 2017; 7:17453.
Martorell-Calatayud C, Michavila-Gómez A, Martorell-Aragonés A, et al. Anti-IgE-assisted desensitization to egg and cow's milk in patients refractory to conventional oral immunotherapy. Pediatr Allergy Immunol 2016; 27:544–546.
Schneider LC, Rachid R, LeBovidge J, et al. A pilot study of omalizumab to facilitate rapid oral desensitization in high-risk peanut-allergic patients. J Allergy Clin Immunol 2013; 132:1368–1374.
Yee CSK, Albuhairi S, Noh E, et al. Long-term outcome of peanut oral immunotherapy facilitated initially by omalizumab. J Allergy Clin Immunol Pract 2019; 7:451–461.
Brandström J, Vetander M, Lilja G, et al. Individually dosed omalizumab: an effective treatment for severe peanut allergy. Clin Exp Allergy 2017; 47:540–550.
MacGinnitie AJ, Rachid R, Gragg H, et al. Omalizumab facilitates rapid oral desensitization for peanut allergy. J Allergy Clin Immunol 2017; 139:873–881.
Langlois A, Lavergne MH, Leroux H, et al. Protocol for a double-blind, randomized controlled trial on the dose-related efficacy of omalizumab in multifood oral immunotherapy. Allergy Asthma Clin Immunol 2020; 16:25.
Andorf S, Purington N, Block WM, et al. Anti-IgE treatment with oral immunotherapy in multifood allergic participants: a double-blind, randomised, controlled trial. Lancet Gastroenterol Hepatol 2018; 3:85–94.
https://clinicaltrials.gov/ct2/show/NCT02402231 . [Accessed 2 February 2023]
Bégin P, Dominguez T, Wilson SP, et al. Phase 1 results of safety and tolerability in a rush oral immunotherapy protocol to multiple foods using Omalizumab. Allergy Asthma Clin Immunol 2014; 10:7.
Zuberbier T, Wood RA, Bindslev-Jensen C, et al. Omalizumab in IgE-mediated food allergy: a systematic review and meta-analysis. J Allergy Clin Immunol Pract 2022; S2213–S2198.
Wood RA, Chinthrajah RS, Eggel A, et al. The rationale for development of ligelizumab in food allergy. World Allergy Organ J 2022; 15:100690.
https://clinicaltrials.gov/ct2/show/NCT04984876 . [Accessed 10 February 2023].
Brandstrom J, Vetander M, Sundqvist AC, et al. Individually dosed omalizumab facilitates peanut oral immunotherapy in peanut allergic adolescents. Clin Exp Allergy 2019; 49:1328–1341.
Arasi S, Nurmatov U, Turner PJ, et al. WAO consensus on DEfinition of Food Allergy SEverity (DEFASE). World Allergy Organ J 2023; 16: (in press).